-
Survival Statistics 101
Survival statistics are important—and sometimes confusing. Cancer Today spoke with statistics experts about what these numbers really mean.
by Ashley P. Taylor
-
“Congrats! You Have the ‘Good’ Cancer”
Many people know thyroid cancer as a cancer type with a relatively good prognosis, but the disease still has profound effects on patients and survivors, writes thyroid cancer survivor Carly Flumer.
by Carly Flumer
-
Learning the Language of Chemotherapy
Cancer patients often do not understand words their doctors use while talking about chemotherapy, but a new video series helps explain these terms.
by Jen Tota McGivney
-
Misunderstandings About Cancer DNA Tests
Many cancer patients who received genomic testing of their cancers in a clinical trial did not fully understand the purpose of the testing.
by Emma Yasinski
-
What Not to Say to a Cancer Patient
When visiting a friend or family member who is sick, it's good to leave platitudes at the door.
by Michael Gavaghen
-
Considering the Term “Cancer Survivor”
A study investigates how people who have been diagnosed with cancer feel about being called survivors.
by Jen Tota McGivney
-
What Do Clinical Trial Endpoints Really Measure?
A study investigates whether a commonly used clinical trial endpoint, progression-free survival, can be used to predict quality of life.
by Jon Kelvey
Cancer Talk
Online Second Opinions
More than half of patients who participated in a program offering online second opinions were recommended a change to their treatment plan.
by Eric Fitzsimmons
Musical Toxicity an Effect of Cancer TreatmentStudy finding cancer treatment affects ability to play or sing music highlights need for physical therapy, experts say.
by Kyle Bagenstose
Treatment Lags Behind Guidelines for Many Men With Prostate CancerGuidelines for treating advanced prostate cancer changed in 2017, but a recent study indicated many patients were not being treated accordingly.
by Laura Gesualdi Gilmore
Treating HER2-ultralow Breast CancerFDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon